What is Anti-HIgG(Fc)-N-MMAF ADC?

This product is an antibody-drug conjugate (ADC) consisting of a polyclonal antibody specific to the Fc region of human IgG, conjugated to the cytotoxic agent monomethyl auristatin F (MMAF) through a non-cleavable linker.

Can Anti-HIgG(Fc)-N-MMAF ADC be used in pre-screening human monoclonal antibodies?

Yes, this ADC is designed to be an efficient and economical option for pre-screening human monoclonal antibodies as potential ADC candidates.

What type of cytotoxicity does MMAF exhibit in the absence of a primary antibody?

The product displays minimal to no toxicity without the presence of a primary antibody, highlighting its specificity and safety in targeting cells.

What makes Anti-HIgG(Fc)-N-MMAF ADC an economical choice in ADC development?

By targeting the Fc region of IgG, this ADC can be used in initial screens to assess the therapeutic potential of various monoclonal antibodies without the need for individual ADC formulations for each antibody.

What safety concerns should be considered when using this ADC?

While the ADC shows minimal toxicity without a primary antibody, its potential effects in complex biological systems should be closely monitored during experimental applications.

Can this ADC be used in conjunction with other therapeutic agents?

Yes, it can potentially be used with other immunotherapeutic agents, especially those that might target different mechanisms or pathways within the immune system.

How is the ADC administered in experimental settings?

The ADC is typically administered via injection in preclinical studies to ensure direct delivery into the circulation or targeted tissues.

Home
Products
Anti-Ab ADCs
IgG Fc
anti-HIgG(Fc)-N-MMAF ADC

anti-HIgG(Fc)-N-MMAF ADC (CAT#: ADC-AA-001)

This ADC product is comprised of an anti-human IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to MMAF. The antibody portion is a secondary antibody and the drug portion, MMAF, is a cytotoxic small molecule which binds to tubulins, interrupts microtubule dynamics, and induces cell death. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Name
IgG Fc

Overview
The fragment crystallizable region (Fc region) is composed of the constant region of the two heavy chains that form the IgG molecule. The Fc region of IgG bears a highly conserved N-glycosylation site. Glycosylation of the Fc fragment is essential for Fc receptor-mediated activity. Fc binds to various cell receptors and complement proteins thus mediating different physiological effects of antibodies, such as opsonization, antibody dependent cellular cytotoxicity (ADCC), degranulation of mast cells, basophils, eosinophils and other processes.

Overview
anti-human IgG Fc specific polyclonal IgG antibody

Species Reactivity
Human

Name
Noncleavable linkers

Description
Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.

Name
MMAF (Monomethyl auristatin F)

Description
Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-001. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

Anti-HIgG(Fc)-N-MMAF ADC demonstrated exceptional binding to human IgG Fc, significantly improving the precision of our cytotoxicity assays.

Excellent

The noncleavable linker ensured stable conjugation, and the MMAF effectively disrupted microtubule dynamics, leading to consistent cell death in our tests.

Excellent

This ADC showed no off-target toxicity, which was crucial for our experiments involving primary antibodies. High specificity and reliable performance.

Excellent

The glycosylation of the Fc region enhanced receptor-mediated activities, making this ADC perfect for our antibody-dependent cellular cytotoxicity studies.

Excellent

Very efficient

The anti-HIgG(Fc) specificity was spot-on, allowing us to accurately pre-screen human monoclonal antibodies as ADC candidates.

Excellent

Creative Biolabs' ADC provided stable and reproducible results, significantly enhancing the efficiency of our immunoassays. Prompt delivery and top-notch quality.

Q: 1: What is Anti-HIgG(Fc)-N-MMAF ADC?
A: This product is an antibody-drug conjugate (ADC) consisting of a polyclonal antibody specific to the Fc region of human IgG, conjugated to the cytotoxic agent monomethyl auristatin F (MMAF) through a non-cleavable linker.
Q: 2: Can Anti-HIgG(Fc)-N-MMAF ADC be used in pre-screening human monoclonal antibodies?
A: Yes, this ADC is designed to be an efficient and economical option for pre-screening human monoclonal antibodies as potential ADC candidates.
Q: 3: What type of cytotoxicity does MMAF exhibit in the absence of a primary antibody?
A: The product displays minimal to no toxicity without the presence of a primary antibody, highlighting its specificity and safety in targeting cells.
Q: 4: What makes Anti-HIgG(Fc)-N-MMAF ADC an economical choice in ADC development?
A: By targeting the Fc region of IgG, this ADC can be used in initial screens to assess the therapeutic potential of various monoclonal antibodies without the need for individual ADC formulations for each antibody.
Q: 5: What safety concerns should be considered when using this ADC?
A: While the ADC shows minimal toxicity without a primary antibody, its potential effects in complex biological systems should be closely monitored during experimental applications.
Q: 6: Can this ADC be used in conjunction with other therapeutic agents?
A: Yes, it can potentially be used with other immunotherapeutic agents, especially those that might target different mechanisms or pathways within the immune system.
Q: 7: How is the ADC administered in experimental settings?
A: The ADC is typically administered via injection in preclinical studies to ensure direct delivery into the circulation or targeted tissues.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-054	Protein A-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-026	anti-MIgG(Fc)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-029	anti-MIgG(Fc)Fab-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)
ADC-AA-051	Protein G-Duocarmycin ADC		Duocarmycins
ADC-AA-031	anti-MIgG(Fc)Fab-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

CAT#	Product Name	Linker	Payload
ADC-AA-063	Anti-HIgG(Fab)-N-MMAF ADC	Noncleavable linkers	MMAF
ADC-AA-037	anti-RIgG(HL)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-046	anti-Rat IgG(HL)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-027	anti-MIgG(Fc)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-008	anti-HIgG(Fc)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

CAT#	Product Name	Linker	Payload
ADC-AA-002	anti-HIgG(Fc)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-W-604	Anti-FUT3-Mc-VC-PABC-MMAF ADC-3	MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)	MMAF (Monomethyl auristatin F)
ADC-AA-009	anti-HIgG(Fc)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-053	Protein A-MMAF ADC		MMAF (Monomethyl auristatin F)
ADC-AA-019	anti-MIgG(Fc)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.